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ttp://dx.doi.org/10.1016/j.ajpath.2013.06.027Cyclin D1 is a component of the core cell-cycle machinery and is frequently overexpressed in breast
cancer. It physically interacts with the tumor suppressor Dmp1 that attenuates the oncogenic signals
from Ras and HER2 by inducing Arf/p53-dependent cell-cycle arrest. Currently, the biological signiﬁ-
cance of Dmp1ecyclin D1 interplay in breast cancer has not been determined. Here, we show that cyclin
D1 bound to Dmp1 to activate both Arf and Ink4a promoters and, consequently, induced apoptosis or
G2/M cell-cycle delay in normal cells to protect them from neoplastic transformation. The cyclin D1e
induced Ink4a/Arf gene expression was dependent on Dmp1 because the induction was not detected in
Dmp1-deﬁcient or DMP1-depleted cells. Arf/Ink4a expression was increased in pre-malignant mammary
glands from Dmp1þ/þ;MMTV-cyclin D1 and Dmp1þ/þ;MMTV-D1T286A mice but signiﬁcantly down-
regulated in those from Dmp1-deﬁcient mice. Selective Dmp1 deletion was found in 21% of the
MMTV-D1 and D1T286A mammary carcinomas, and the Dmp1 heterozygous status signiﬁcantly accel-
erated mouse mammary tumorigenesis with reduced apoptosis and increased metastasis. Overall, our
study reveals a pivotal role of combined Dmp1 loss and cyclin D1 overexpression in breast cancer.
(Am J Pathol 2013, 183: 1339e1350; http://dx.doi.org/10.1016/j.ajpath.2013.06.027)Supported by ACS RSG-07-207-01-MGO, 5R01CA106314, and Direc-
tor’s Challenge Award #20595 from Wake Forest University Health
Sciences (K.I.); R01CA118329 (G.K.); ACS 116403-RSG-09-082-01-
MGO and 5R01CA106314 (G.S.); institutional grant IRSC-GTS: 37540
(S.Z.); and the Susan G. Komen Foundation postdoctoral fellowship
KG080179 (P.T.). The Cell and Virus Vector Core Laboratory of the
Comprehensive Cancer Center at Wake Forest University Health Sciences
provided access to cell culture materials.As a key sensor and integrator of extracellular signals in
early-to-mid G1 phase, cyclin D1 deregulation, including
chromosomal translocation, gene ampliﬁcation, or reduced
degradation, results in tumorigenesis and has been linked to
breast cancer and other human cancers.1,2 Cyclin D1 drives
cells to enter S phase by binding and activating the Cdk4/6
kinase. The cyclin D1/Cdk4 complex phosphorylates the
retinoblastoma protein (pRb), which releases E2F tran-
scriptional factors from pRb constraint. E2Fs then activate
the transcription of genes required for cells to enter S
phase.3 Apart from its catalytic function, cyclin D1 also
exerts a transcription regulation without the participation of
Cdks, even though it is not a transcriptional factor. Cyclin
D1 executes the transcriptional regulation through its
interaction with transcriptional factors and chromatin
modiﬁers.4,5 For instance, it directly binds and activates
estrogen receptor a (ERa) in breast cancer cell lines in a
CDK-independent fashion.6 By contrast, cyclin D1 interacts
and inhibits the transcriptional activity of androgen recep-
tor (AR), Myb-related protein B (B-Myb), E1A-bindingstigative Pathology.
.protein p300, and NF-kB.7e10 Overall, these studies sug-
gested that cyclin D1 regulates cell proliferation, growth,
and differentiation, and its transcriptional regulatory ac-
tivity has great potential signiﬁcance in human cancer
progression.5,11
Among known cyclin D1eassociated transcriptional
factors, cyclin Deinteracting Myb-like Protein 1 (Dmp1;
alias Dmtf1) is a bona ﬁde tumor suppressor.12,13 Dmp1
directly binds and activates Arf, thereby inducing Arf-
p53edependent cell-cycle arrest.14 Dmp1-deﬁcient cells can
be transformed by oncogenic Ras alone without altering the
status of Arf and p53 genes, suggesting that the Arf-p53
Zhu et alpathway is signiﬁcantly attenuated inDmp1-deﬁcient cells.13
Ectopically expressed Dmp1 inhibits the growth of breast
cancer cells with wild-type p53, indicating that p53 is a crit-
ical target for Dmp1 to exhibit its biological activity.15 Both
Dmp1-null and Dmp1-heterozygous mice are prone to
develop tumors, and a wild-typeDmp1 allele is often retained
in tumors from Dmp1-heterozygous mice. This suggests that
Dmp1 is haploinsufﬁcient as a tumor suppressor.12,13,16
Our recent study in MMTV-neu mice showed that mam-
mary carcinogenesis was signiﬁcantly accelerated in both
Dmp1þ/ and Dmp1/ backgrounds, with no difference
between groups that lacked one or both Dmp1 alleles.
Hemizygous Dmp1 deletion was found in >50% of neu
mammary carcinomas accompanied with signiﬁcant down-
regulation of p19Arf and p21Cip1/WAF1, indicating that Dmp1
is a physiological regulator of the Arf-p53 pathway in vivo.17
Consistent with the mouse model studies, the loss of
heterozygosity of DMP1 was found in nearly 45% of human
breast carcinomas and mutually exclusive with that of
INK4a/ARF and P53, suggesting primary involvement of
DMP1 in human mammary carcinogenesis.15
Cyclin D1 physically interacts with Dmp1, and antago-
nizes its ability of activating the CD13/aminopeptidase N
promoters in the absence of functional Cdks.18 However, by
an unknown mechanism, Dmp1 and cyclin D1 collaborate
to activate the Arf promoter, which suggests that whether
cyclin D1 acts as a corepressor or coactivator of Dmp1 is
dependent on the context of a target gene.19 Although Dmp1
and cyclin D1 play vital roles in breast cancer prevention
and development, respectively, the biological functions and
signiﬁcance of Dmp1ecyclin D1 interaction in breast
cancer remain to be determined. We conducted the current
study to elucidate the cooperative role of cyclin D1 and
Dmp1 in breast cancer development. We showed that Dmp1
modulated the activation of the Arf/Ink4a tumor suppressor
pathways induced by cyclin D1 overexpression. We crossed
the MMTV-cyclin D1 and MMTV-D1T286A mice with
Dmp1-deﬁcient mice and found that Dmp1 heterozygosity
signiﬁcantly accelerated cyclin D1einduced mammary
carcinogenesis. We also observed the metastasis of cyc-
lin D1einduced mammary tumors in a Dmp1-deﬁcient
background.
Materials and Methods
Cell Culture and Luciferase Reporter Assays
Wild-type and Dmp1-null murine embryonic ﬁbroblasts
(MEFs) were established from 13.5-day-old embryos as
previously described.12 MEF, NIH 3T3, and human mam-
mary epithelial cells were cultured as described previ-
ously.12,15,17 To study the responsiveness of the Arf/Ink4a
promoters to cyclin D1 and D1T286A, 2  105 cells were
seeded into 60-mm-diameter culture dishes 24 hours before
transfection, and then transfected with 4 mg of luciferase
reporter DNA with or without increasing amount of1340pFLEX1-cyclin D1, pFLEX1D1T286A,20 or pFLEX1-cyclin
D1D21 and 4 mg of a control plasmid with b-actin promotere
driven secreted alkaline phosphatase (SEAP).18,19,21 Gene-
Juice transfection reagent (Novagen; EMD Millipore,
Billerica, MA) was used in all transfections.Chromatin Immunoprecipitation
Tissue and cell chromatin immunoprecipitations (ChIP) were
performed as described previously.19,22e24 Brieﬂy, in tissue
ChIP, lysates from Dmp1þ/þ;MMTV-neu tumors were
precipitated with antibodies against cyclin D1 (SP4; Neo-
Markers/Lab Vision, Fremont, CA, and sc-753; Santa Cruz
Biotechnology, Santa Cruz, CA) and incubated at 4C over-
night. After reverse cross-linking, the immunoprecipitated
DNA was ampliﬁed by PCR after being mixed with 1 mCi of
[a-32P]dATP (PerkinElmer, Waltham, MA) and separated on
a 10% nondenaturing polyacrylamide gel. In cell ChIP, wild-
type and Dmp1-null MEFs were infected with lentivirus
expressing hemagglutinin (HA)-cyclin D1. Forty-eight hours
after infection, the cell lysates were precipitated with anti-HA
afﬁnity gel (E6779; Sigma-Aldrich, St. Louis, MO). Mouse
IgG-agarose (A0919; Sigma-Aldrich) was used as a negative
control. For the detection of cyclin D1 on the Arf promoter,
a sense primer 50-ACTCGGAGCAAGGGAAACCT-30 and
an anti-sense primer 50-TAGCAGTAGCTGCGCCCTTT-30
were used. For the detection of cyclin D1 on the Ink4a
promoter, a sense primer 50-GCAAATAGCGCCACCTAT-
GG-30 and an anti-sense primer 50-CTGCTCCAGATGG-
CTCTCCT-30 were used.Retrovirus and Lentivirus Production
For retrovirus production, 293T cells were transfected with
pSRaMSV-tkneo vector, pSRaMSV-cyclin D1-tkneo,
pSRaMSV-D1T286A-tkneo, pSR vector, or pSR-1131
(DMP1 shRNA)16 together with a helper retrovirus plasmid.
Viruses were harvested and used to infect cells as previously
described.19 For lentivirus production, 293T cells were
transfected with pSL4-HA, pSL4-HA-cyclin D1, or pSL4-
HA-cyclin D1T286A with helper lentivirus plasmids
including VSVG, RSV-REV, and PMDL g/p RRE. Viruses
were harvested 48 hours after transfection. For preparation
of doxycycline-inducible cyclin D1, the cyclin D1 cDNA
was PCR ampliﬁed by Pfu DNA polymerase and then
subcloned downstream of a 6xTRE minimal promoter in an
all-in-one doxycycline-inducible vector that expresses
rtTA-advanced protein, generated by our colleagues.Real-Time PCR
Analysis of Dmp1 gene copy number and quantiﬁcation of
Dmp1, p14ARF, p19Arf, p21Cip1/WAF1, p16Ink4a, and CYCLIN
D1 mRNAs were conducted by real-time PCR TaqMan
assays on an Applied Biosystems ABI 7500 Real-Time PCRajp.amjpathol.org - The American Journal of Pathology
DMP1-Cyclin D1 in Breast Cancermachine (Life Technologies, Foster City, CA). b-Actin was
used as internal control.22e24
Western Blot Analysis
Proteins were extracted from cell lysates in ice-cold EBC
buffer with proteinase inhibitors.25 After being separated by
gel electrophoresis and transferred to nitrocellulose mem-
branes, proteins were detected by immunoblotting with
afﬁnity-puriﬁed polyclonal antibodies for Dmp1 [Rabbit
Antibody D (RAD)],22 cyclin D1 (sc-753; Santa Cruz Bio-
technology), p53 (sc-6243G; Santa Cruz Biotechnology),
Mdm2, or HDM2 (ab16896 [2A10]; Abcam, Cambridge,
UK), p19Arf (sc-32748; Santa Cruz Biotechnology), p14ARF
(sc-53639; Santa Cruz Biotechnology), cleaved poly(ADP-
ribose) polymerase (PARP) (#AF-600-NA; R&D Systems,
Minneapolis, MN), cleaved caspase 3 (#9661; Cell Signaling
Technology, Danvers, MA), p16Ink4a (sc-74401; Santa Cruz
Biotechnology), p21CIP1/WAF1 (sc-397G; Santa Cruz Bio-
technology), or b-actin (sc-1615, sc-47778; Santa Cruz
Biotechnology), followed by incubation with horseradish
peroxidaseeconjugated secondary antibodies, and visuali-
zation using an enhanced chemiluminescence detection kit
(PerkinElmer).
Dmp1þ/; and Dmp1/; MMTV-cyclin D1 and MMTV-
D1T286A Compound Mice
The mouse model studies were performed according to
a protocol approved by the Institutional Animal Care and
Use Committee of Wake Forest University School of
Medicine. Dmp1-heterozygous females were backcrossed to
the same FVB/NJ males (The Jackson Laboratory, Bar
Harbor, ME) for more than eight generations to obtain
Dmp1þ/ mice with >99% FVB/NJ background overall. A
male MMTV-cyclin D1 mouse (provided by Dr. E.V.
Schmidt, Harvard Medical School)26 or MMTV-D1T286A
mouse (provided by Dr. J.A. Diehl, University of Pennsyl-
vania)27 in a pure FVB/NJ background was crossed with a
Dmp1þ/ female to obtain Dmp1þ/;MMTV-cyclin D1 and
Dmp1þ/;MMTV-D1T286A mice. Then Dmp1þ/;MMTV-
cyclin D1 and Dmp1þ/;MMTV-D1T286A compound
transgenic mice were further crossed with Dmp1þ/ mice to
obtain >15 mice with each genetic background. Littermate
wild-type mice were used as controls.
Cell-Cycle Analysis
Wild-type andDmp1-null MEFswere infected with lentivirus
carrying empty vector or expressing cyclin D1 or D1T286A.
Forty-eight hours after infection, cells were trypsinized,
washed with PBS, ﬁxed in 70% of ethanol, treated with pro-
pidium iodide and ribonuclease A, and then run through
a ﬂow cytometer (Accuri; Becton Dickinson, Franklin Lakes,
NJ). Cell-cycle distributions were analyzed by ModFit LT
software version 3.0 (Verity Software House, Topsham,ME).The American Journal of Pathology - ajp.amjpathol.orgImmunohistochemical Staining
Immunohistochemical staining of tissues and tumors were
conducted as described previously.15 The following antibodies
were used for immunohistochemistry with formalin-ﬁxed,
parafﬁn-embedded sections: Ki-67 (SP6; NeoMarkers/Lab
Vision), cyclin D1 (SP4; NeoMarkers/Lab Vision), cleaved
caspase-3 (#9661; Cell Signaling Technology), cytokeratin 8
(ab59400; Abcam), cytokeratin 14 (ab7800; Abcam), and ERa
(sc-542; Santa Cruz Biotechnology).
In Vitro Mutagenesis
The murine Ink4a promoter Dmp1-binding site deletion/
point mutants were generated by use of an in vitro
mutagenesis kit (Stratagene; Agilent Technologies, Santa
Clara, CA). For deletion mutagenesis, the sense primer
50-CCATCCCTTTCCCCTCCCGTGGGGGGAACAGCA-
GTG-30 and its reverse complementary sequence were used.
For point mutagenesis, the sense primer 50-CCTTTCCCC-
TCCCCCTTCCGGAGGTGGGGGGAA-30 and its reverse
complementary sequence were used.
Electrophoretic Mobility Shift Assay
Recombinant DMP1 protein was prepared in Sf9 cells.25
Electrophoretic mobility shift assays were performed using
32P-labeled oligonucleotide probe covering the DMP1/Ets
site on murine or human INK4a promoter obtained by
annealing oligonucleotide 50-GGGATCCCTTTCCCCTCCC-
CCATCCGGAGGTGGGGGGAACAGCA-30 (mouse sense
strand) or 50-GGGCTGGGATCAGCTCTCAGCATCCGG-
AAGCCTTTGCCTACTAG-30 (30911 human sense strand)
or 50-GGGATAGACGTGAGCCACC-GCATCCGGACT-
TTCCTTTTATGTAA-30 (33549 human sense strand) (the
DMP1/Ets consensus sequence is underlined) with a com-
plementary antisense strand. The probe containing the
DMP1/Ets site on murine Arf promoter has been described.14
For competition experiments, a 50-fold excess of unlabeled
oligonucleotides were added to reaction mixtures before
probe incubation.
Statistical Analysis
Statistical differences of survival in Dmp1þ/þ;MMTV-cyclin
D1, Dmp1þ/;MMTV-cyclin D1, Dmp1þ/þ;MMTV-D1T286A,
and Dmp1þ/;MMTV-D1T286A mice were analyzed by Med-
calc software version 12.7.0 (Mariakerke, Belgium). Statistical
analyses for all experiments were conducted using unpaired
Student’s t-tests.
Results
Dmp1 Is Essential to Cyclin D1eMediated Activation of
the Arf and Ink4a Promoters
We previously demonstrated that Dmp1 directly binds and
activates the Arf promoter.14,28 To determine whether Dmp11341
Zhu et alalso regulates Ink4a gene expression, we analyzed the
murine Ink4a promoter and found a candidate Dmp1/Ets
consensus sequence (TCCGGATGG: 178 to 166 rela-
tive to the transcription initiation site; two mismatches
from the originally reported consensus sequences25 at both
ends; the DMP1/Ets consensus sequence is underlined)
(Supplemental Figure S1A). In electrophoretic mobility shift
assay studies, recombinant Dmp1 directly associated with
the oligonucleotide with this sequence at a relatively low
afﬁnity compared to its binding to the oligonucleotide with
the Dmp1 consensus in the Arf promoter (Supplemental
Figure S1B). In reporter assays, Dmp1 activated the Ink4a
promoter by sixfold to eightfold over a control vector,
but this effect was not observed in reporter constructs
with the Dmp1/Ets site mutated or deleted (Supplemental
Figure S1C), suggesting that this consensus was necessary
for Dmp1-mediated Ink4a transactivation. We also found
two consensus sequences of Dmp1 in the human INK4a
promoter, which was bound and activated by Dmp1 up to
threefold over a control vector (Supplemental Figure S1, D
and E). Thus, our data support that Dmp1 regulates Ink4a
expression in both humans and mice.
Cyclin D1 induces cell cycle arrest, senescence, and
apoptosis when overexpressed.29 Thus, we investigated the
potential effect of cyclin D1 on the Arf and Ink4a
promoters. Both wild-type cyclin D1 and its constitutively
active mutant D1T286A activated the Arf and Ink4a
promoters, although the former showed better response
than the latter (sevenfold versus fourfold) (Figure 1A).
Cyclin D1emediated activation of Arf and Ink4a was also
observed in Dmp1þ/þ MEFs, but this effect was abrogated
in Dmp1/ MEFs (Figure 1B). However, ectopically
expressed Dmp1 in Dmp1/ MEFs restored cyclin
D1einduced luciferase activity mediated by the Arf and
Ink4a promoters, suggesting that Dmp1 is indispensable
for cyclin D1eactivated Arf and Ink4a expression
(Figure 1C). Moreover, a cyclin D1 mutant, D1D142e253
that is deﬁcient in Dmp1 binding,21 failed in activating
either the Arf or Ink4a promoter, suggesting that the effect
of cyclin D1 on these promoters depended on cyclin
D1eDmp1 interaction (Figure 1, A and C). Additionally,
the transcription of endogenous p19Arf and p16Ink4a was
promoted by ectopic cyclin D1 or D1T286A in wild-type
MEFs, but this effect was diminished in Dmp1-null
MEFs (Figure 1D).
Consistently, we observed the recruitment of cyclin D1
on the Arf and Ink4a promoters in ChIP assays in wild-type
MEFs infected with lentivirus expressing HA-tagged cyclin
D1, but this binding was not detected in Dmp1-null MEFs
(Figure 1E). The association of endogenous cyclin D1 with
the Arf and Ink4a promoters was conﬁrmed by ChIP assays
using lysates from MMTV-neu mammary tumors that
expressed high levels of both Dmp1 and cyclin D1
(Figure 1F).17,30 Collectively, these data suggest that cyclin
D1 binds and activates both the Arf and Ink4a promoters,
and this regulation depends on the presence of Dmp1.1342Cyclin D1 Induces G2/M Cell-Cycle Delay and Apoptosis
Mediated by Dmp1
Both cyclin D1 and D1T286A increased p19Arf protein level
when wild-type MEFs were starved in serum-free medium
for 48 hours. Those cells underwent apoptosis as indicated
by increased levels of cleaved PARP and caspase-3.
However, there was no increase of p19Arf or induction of
cleaved PARP and caspase-3 in Dmp1/ MEFs on cyclin
D1 or D1T286A overexpression (Figure 2A). We also
stained the cells with annexin V and determined apoptotic
cells by ﬂow cytometry. Ectopic expression of cyclin D1
or D1T286A resulted in 20% increase of apoptosis
in Dmp1þ/þ MEFs, but this effect was not observed in
Dmp1/ MEFs (data not shown). Consistent with the
aforementioned data, ectopic expression of cyclin D1 and
D1T286A in wild-type MEFs by lentiviral infection
promoted p19Arf expression. We also detected increased
expression of p16Ink4a protein in those cells, although
neither p19Arf nor p16Ink4a showed this response toward
cyclin D1 in Dmp1/ MEFs (Figure 2B).
We further investigated the potential effect of cyclin D1
on cell-cycle proﬁle. Ectopic expression of cyclin D1 and
D1T286A through lentiviral infection led to G2/M phase
delay of wild-type MEFs, but they only slightly increased
the S phase fraction of Dmp1/ MEFs (Figure 2, C and D),
indicating that cyclin D1emediated G2/M phase delay of
the cell cycle depends on Dmp1.
Similar to the ﬁndings in MEFs, both p14ARF and
p16INK4a mRNA levels increased in human mammary
epithelial cells when ectopic cyclin D1 was expressed by
a doxycycline-inducible system (Figure 3A). The protein
level of p14ARF was increased accordingly, whereas the
p16INK4a level was too low to be detected (Figure 3A). With
DMP1 knockdown by its shRNA15,16 in human mammary
epithelial cells, ectopic cyclin D1 or D1T286A failed in
altering p14ARF or p16INK4a transcription (Figure 3B),
although the two cyclin D1 proteins were expressed at
comparable levels despite Dmp1 expression (Figure 3B).
Moreover, human mammary epithelial cells underwent
G2/M phase delay on cyclin D1 and D1T286A over-
expression, whereas DMP1 silencing abolished this effect
(Figure 3C). Taken together, our data indicate that elevated
cyclin D1 expression activates Arf/Ink4a genes in both mice
and humans, and induces G2/M phase delay or apoptosis in
a Dmp1-dependent fashion.
Dmp1 Is Required for the Increased p19Arf/p16Ink4a
Expression in Mammary Tumors of MMTV-D1 and
D1T286A Mice
Because Dmp1 deletion was frequently detected (approxi-
mately 50%) in mammary tumors of MMTV-neu transgenic
mice, whereas the Ink4a/Arf or p53 locus deletion was not
observed,17 we next focused on the Dmp1 gene copy
number study in mammary tumors of MMTV-D1 andajp.amjpathol.org - The American Journal of Pathology
Figure 1 Both p19Arf and p16Ink4a promoters are activated by cyclin D1 and the cyclin D1T286A mutant. A: The Arf (281) or Ink4a (400) promoter
luciferase construct was cotransfected with indicated amounts of cyclin D1 [wild-type (wt)], D1T286A (D1TA), or D1D142e253 (D1D)21 expression vectors in
NIH 3T3 cells. The numbers show the fold activation of the luciferase reporter normalized by internal controls of SEAP. B: The Arf (281) or Ink4a (400)
promoter luciferase construct was cotransfected with increasing amounts of cyclin D1 expression vector in Dmp1þ/þ or Dmp1/ MEFs. The numbers show the
fold activation of the luciferase reporter normalized by internal controls of SEAP. C: Luciferase reporter construct encoding Arf (281) promoter or Ink4a
(400) promoter was cotransfected with 1 mg of pFLEX1-Dmp1 together with either 3 or 5 mg of pFLEX1-cyclin D1 or pFLEX1-D1D142e253 into Dmp1-null
MEFs. The numbers show the fold activation of the luciferase reporter normalized by internal controls of SEAP. D: Primary Dmp1þ/þ (black bars) or Dmp1/
(white bars) MEFs were infected with retrovirus carrying an empty vector or vector expressing cyclin D1 or D1T286A protein. After neomycin selection, cells
were harvested for the analysis of Arf and Ink4a mRNA levels by real-time PCR using b-actin as a control. E: ChIP analysis of cyclin D1 binding to the Arf and
Ink4a promoters in Dmp1þ/þ and Dmp1/ MEFs infected with lentivirus expressing HA-cyclin D1. Lysates derived from Dmp1þ/þ and Dmp1/ MEFs were
immunoblotted for Dmp1 and HA. b-Actin was used as a loading control. The asterisk indicates a nonspeciﬁc band. F: ChIP analysis for the binding of
endogenous cyclin D1 to the Arf and Ink4a promoters in MMTV-neu tumors. Tissue ChIP was conducted with formalin-ﬁxed tumors from the MMTV-neu mice
with wild-type Dmp1. The cyclin D1 protein was precipitated by two different antibodies to cyclin D1 (SP4 and H295). Data are means  SD from n Z 3
individual experiments (AeD). Ab, antibody; pro, promoter.
DMP1-Cyclin D1 in Breast CancerMMTV-D1T286A mice. We found one Dmp1 allele deletion
in two of nine mammary tumors fromMMTV-D1mice and 2
of 10mammary tumors fromMMTV-D1T286Amice (4 of 19,
or 21%) (Supplemental Figure S2A). Signiﬁcant induction of
the p19Arf and p16Ink4a (2-fold to 18-fold) gene transcription
was detected in more than half of Dmp1 wild-type mammary
tumors compared to those in normal mammary glands.
Markedly, among four tumors with oneDmp1 allele lost, two
tumors showed signiﬁcant down-regulation of p19Arf
(Supplemental Figure S2B), and three exhibited very low
p16Ink4a expression (Supplemental Figure S2C). A previous
study discovered that the p53 pathway can be inactivatedThe American Journal of Pathology - ajp.amjpathol.orgby mutations in MMTV-D1 and D1T286A tumors.27 To
determine whether the increased p19Arf expression was due to
p53 inactivation,28 we sequenced the region of the p53 gene
encoding its DNA-binding domain. One MMTV-D1 tumor
and oneMMTV-D1T286A tumor had p53mutations, whereas
others with elevated p19Arf expression maintained wild-type
p53. As expected, tumors with p53 mutations showed
a dramatically increased level of p19Arf (Supplemental
Figure S2B). In summary, these observations indicate that
Dmp1 is essential for cyclin D1eactivated p19Arf/p16Ink4a
expression in mammary tumors of Dmp1þ/þ;MMTV-cyclin
D1 and Dmp1þ/þ;MMTV-D1T286A mice.1343
Figure 2 Overexpression of cyclin D1 or
D1T286A induces apoptosis and G2/Mphase delay in
MEFs. A: Primary Dmp1þ/þ and Dmp1/ MEFs were
infected with control retrovirus (V) or retrovirus
expressing cyclin D1 (D1) or D1T286A (TA) protein.
Cells were starved for 48 hours in serum-freemedium
and then harvested for immunoblot analysis of
cyclin D1, p19Arf, PARP, cleaved caspase-3, and
Dmp1. b-Actin was used as a loading control. B:
Primary Dmp1þ/þ and Dmp1/ MEFs were infected
with control lentivirus or lentivirus expressing HA-
tagged cyclin D1 or D1T286A protein. Cells were
harvested after 48 hours for immunoblot analysis of
HA-cyclin D1, p19Arf, p16Ink4a, and Dmp1. b-Actin
was used as a loading control. C: Representative
images of cell-cycle proﬁles of Dmp1þ/þ and
Dmp1/ MEFs infected by lentivirus carrying an
empty vector or expressing cyclin D1 or D1T286A
(T286A) and stainedwith propidium iodide 48 hours
after infection. D: Quantiﬁcation of ﬂow cytometric
analyses was from three independent experiments.
Error bars indicate means  SD. FL-2A, ﬂuorescent
pulse-area; wt, wild-type. *P < 0.05.
Zhu et alCyclin D1e and D1T286A-Induced Mammary
Carcinogenesis Is Accelerated in Dmp1þ/ Mice
To study whether there is any cooperation betweenDmp1 loss
and cyclin D1 overexpression in vivo, we crossed MMTV-
cyclin D1 andMMTV-D1T286Amice withDmp1-null mice to
generate the compound mice (Supplemental Figure S3).
Consistent with a previous study,27 both cyclin D1 and
D1T286A were highly expressed in mammary glands of the
transgenic mice, and D1T286A showed increased nuclear
intensity in mammary epithelial cells relative to these in the
micewithwild-type cyclinD1 (Supplemental Figure S4A).We
did not detect cyclin D1 or D1T286A expression in other
organs. Dmp1 showed substantially reduced expression in the
mammary glands ofDmp1þ/mice compared to these inwild-
type mice (Supplemental Figure S4B). We next assessed the
proliferation and p19Arf/p16Ink4a expression in pre-malignant1344mammary glands from female mice between the ages of 8
and 10 months. The percentages of Ki-67epositive cells were
signiﬁcantly increased in the mammary glands of Dmp1þ/;
MMTV-cyclin D1 and Dmp1þ/;MMTV-D1T286A mice over
these in Dmp1þ/þ;MMTV-cyclin D1 and Dmp1þ/þ;MMTV-
D1T286Amice (Figure 4A). Consistentwith our observation in
mammary tumors (Supplemental Figure S2, B and C), both
p19Arf and p16Ink4a mRNA levels were signiﬁcantly increased
(5-fold to 35-fold for p19Arf, 4-fold to 9-fold for p16Ink4a) in
mammary glands ofDmp1þ/þ;MMTV-cyclinD1 andDmp1þ/þ;
MMTV-D1T286A mice compared to their counterparts without
theCYCLIND1 transgene.On the other hand, the p19ArfmRNA
levels were signiﬁcantly decreased in mammary glands from
both Dmp1þ/ and Dmp1/ mice compared to those from
Dmp1þ/þ mice (Figure 4, B and C), whereas p16Ink4a showed
marked reduction only inmammary glands fromDmp1/mice
(Figure 4D). Taken together, these ﬁndings suggest that cyclinajp.amjpathol.org - The American Journal of Pathology
Figure 3 Overexpression of cyclin D1 activates
both p14ARF and p16INK4a in human mammary
epithelial cells (HMECs). A: HMECs were infected
with lentivirus expressing doxycycline (Dox)-
induced cyclin D1. After puromycin selection,
0.5 mg/mL Dox was added, and cells were har-
vested after 0, 24, 48, and 96 hours, respectively.
p14ARF (light gray bars) and p16INK4a (dark gray
bars) mRNA levels measured by real-time PCR using
b-actin as a control. Cyclin D1 and p14ARFex-
pression were analyzed by immunoblots with
b-actin as a loading control. B: HMECs were
manipulated to coexpress control or DMP1 shRNA
(Ctrl) and cyclin D1 (D1) or D1T286A (D1TA) as
indicated. Real-time PCR analysis of p14ARF (light
gray bars) and p16INK4a (dark gray bars) mRNA
levels after normalized against b-actin. Immuno-
blot analysis of Dmp1 and HA-tagged cyclin D1
expression. b-Actin was used as loading control.
The asterisk indicates nonspeciﬁc bands. C: HMEC
cells were treated as in B and stained with propi-
dium iodide followed by ﬂow cytometric analysis
(top panel). Quantiﬁcation of cell-cycle distribu-
tion is shown in the bottom panel.
DMP1-Cyclin D1 in Breast CancerD1overexpression inmammary glands up-regulates both p19Arf
and p16Ink4a in Dmp1þ/þ mice, but this regulation is compro-
mised in Dmp1-deﬁcient backgrounds.
We established long-term murine cohorts to assess the
effect of cyclin D1 overexpression and Dmp1 loss on tumor
formation in these transgenic mice. We focused on mammary
tumor development in Dmp1þ/mice because the Dmp1/;
MMTV-cyclin D1 and Dmp1/;MMTV-D1T286A mice
frequently developed lung carcinomas or had high incidence
of deaths in the early months after birth for unknown reasons
before they developed mammary tumors. This design was
also clinically relevant, because human breast cancers
showed hemizygous deletion of human DMP1 (hDMP1)
in nearly half of the cases, whereas biallelic deletion of
hDMP1 was rare.15 The cyclin D1e and D1T286A-inducedThe American Journal of Pathology - ajp.amjpathol.orgmammary tumor development was signiﬁcantly accelerated
in Dmp1þ/ mice, with an estimated median disease-free
survival from 810 to 600 days (P Z 0.0238) for wild-type
cyclin D1, and from 730 to 645 days in D1T286A (P Z
0.0284) (Figure 5A). There were higher percentages of
Dmp1þ/;MMTV-cyclin D1 and Dmp1þ/;MMTV-D1T286A
mice developing mammary tumors, with shorter survival
times than those of the Dmp1 wild-type cohorts (Table 1). In
genomic DNA analyses, mammary tumors of Dmp1þ/mice
retained a wild-type Dmp1 allele in all of the seven tumors
examined (Figure 5A), conﬁrming the haploinsufﬁciency of
Dmp1 in suppressing cyclin D1edriven tumor formation.
Dmp1þ/þ; and Dmp1þ/; MMTV-cyclin D1 and MMTV-
D1T286A mice developed mammary ductal adenocarci-
nomas. The mammary tumors from Dmp1þ/þ;MMTV-cyclin1345
Figure 4 Mammary glands from Dmp1þ/þ;MMTV-cyclin D1 and Dmp1þ/þ;MMTV-D1T286A mice show lower proliferation and increased Arf/Ink4a expression.
A: Mammary tissues derived from MMTV-cyclin D1 and Dmp1þ/þ;MMTV-D1T286A mice showed increased proliferation at Dmp1 heterozygous background.
Representative images of Ki-67 immunostaining (red) in mammary glands from Dmp1þ/þ; and Dmp1þ/; MMTV-cyclin D1, and MMTV-D1T286A mice. Nuclei were
counterstained with hematoxylin (blue). Scale bars: 100 mm. Quantiﬁcation of Ki-67epositive cells per mammary gland section is shown. Error bars indicate
means  SD (nZ 3). *P < 0.05, **P < 0.01. BeD: Real-time PCR analysis of Dmp1, p19Arf, and p16Ink4a mRNA levels in mammary glands from MMTV-cyclin D1
and MMTV-D1T286A mice in Dmp1þ/þ, Dmp1þ/, and Dmp1/ backgrounds. Data were normalized against b-actin mRNA levels. Gray columns represent the
samples from MMTV-cyclin D1 mice and black columns represent the samples from MMTV-cyclin D1T286A mice. N, normal mammary gland from nontransgenic
mice.
Zhu et alD1 and Dmp1þ/þ;MMTV-D1T286A mice showed squamous
metaplasia and microinvasion as indicated by blurred
epithelialestromal interface in some glands and a correspond-
ing tissue desmoplasia, whereas the tumors from Dmp1þ/;
MMTV-cyclin D1 and Dmp1þ/;MMTV-D1T286A mice yiel-
ded a more aggressive phenotype as measured by an increased
nuclear/cytoplasmic ratio, nuclear pleomorphism, and layers of
disorganized epithelium (Figure 5B). Moreover, mammary
tumors from Dmp1þ/þ;MMTV-cyclin D1 and Dmp1þ/þ;
MMTV-D1T286A mice displayed a signiﬁcantly higher rate of
apoptosis compared to those from Dmp1þ/;MMTV-cyclin
D1 and Dmp1þ/;MMTV-D1T286A mice (Figure 5C), as
indicated by cleaved caspase-3 staining (percentage of cleaved
caspase-3epositive cells: 3.83% in Dmp1þ/þ versus 0.11% in
Dmp1þ/, P < 0.01).
Most human breast carcinomas with high cyclin D1 levels
also express ER, and a large portion ofmammary tumors from
MMTV-cyclin D1 and MMTV-D1T286A mice with intact
Dmp1 are ER-positive.27 Thus, we wanted to determine
whether cyclinD1einducedmammary tumors on theDmp1þ/
background retained ERa expression. Our immunohistochem-
ical analyses revealed >50% of mammary tumors (12 of 21)
from Dmp1þ/;MMTV-cyclin D1 and Dmp1þ/;MMTV-
D1T286A mice were still ERa-positive (Supplemental
Figure S5), suggesting that the loss of Dmp1 did not change
the estrogen dependence of cyclin D1einduced mammary
tumors.1346Frequent Metastasis of Mammary Tumors in Dmp1þ/;
MMTV-cyclin D1 Mice
Apart from mammary adenocarcinomas, a small number
of other tumor types, including lymphoma and sarcoma,
were also found in both Dmp1þ/þ and Dmp1þ/ cohorts
(Table 1). Of note, lung carcinomas were only found in
Dmp1þ/ mice, conﬁrming the haploinsufﬁciency of Dmp1
in lung cancer suppression.16,31 Importantly, four of nine
mammary tumors from Dmp1þ/;MMTV-cyclin D1 (multi-
parous) mice and one of seven tumors from Dmp1þ/;
MMTV-D1T286A (nulliparous) mice metastasized to other
organs, including liver, ovary, and uterus (Table 1 and
Figure 6A). Intense cyclin D1 staining was detected in the
metastatic tumors but not in adjacent normal tissues
(Figure 6B). The high expression of human CYCLIN D1
transgene in both primary mammary and metastatic tumors
was conﬁrmed by real-time PCR studies (Figure 6C).
Furthermore, both primary and metastatic tumors expressed
cytokeratin 8 and 14 (Figure 6D), indicating that they
derived from the same epithelial origin. Finally, we still
detected low levels of Dmp1 in the metastatic tumors, as in
primary tumors, suggesting that they still retained the one
Dmp1 allele (Figure 6D). In summary, these results suggest
that Dmp1 reduction due to its heterozygosity promotes the
metastasis of cyclin D1e and D1T286A-initiated mammary
tumors.ajp.amjpathol.org - The American Journal of Pathology
Figure 5 Cyclin D1e and D1T286A-induced
mammary carcinogenesis is accelerated in Dmp1þ/
mice. A: Tumor-free survival of Dmp1þ/þ;MMTV-cyclin
D1 (blue) and Dmp1þ/;MMTV-cyclin D1 (red) com-
pound transgenic mice (left panel) and Dmp1þ/þ;
MMTV-DT286A (blue) and Dmp1þ/;MMTV-DT286A
(red) compound transgenic mice (center panel).
Cyclin D1emediated-tumor development was sig-
niﬁcantly more accelerated in Dmp1þ/ than in
Dmp1þ/þ genetic background. PCR conﬁrmed reten-
tion of the wild-type Dmp1 locus in mammary carci-
nomas from Dmp1þ/;MMTV-cyclin D1 and Dmp1þ/;
MMTV-D1T286A mice (right panel). MMTVD1, MMTV-
cyclin D1. B: Representative images of mammary
adenocarcinoma from Dmp1þ/þ;MMTV-cyclin D1
and Dmp1þ/;MMTV-cyclin D1 mice and Dmp1þ/þ;
MMTV-D1T286A and Dmp1þ/;MMTV-D1T286A mice.
Histological sections were stained with H&E. C:
Representative images of immunostaining for cleaved
caspase-3 (red) in mammary tumors from Dmp1þ/þ;
MMTV-cyclin D1, Dmp1þ/þ;MMTV-D1T286A, Dmp1þ/;
MMTV-cyclin D1, and Dmp1þ/;MMTV-D1T286A mice.
Nuclei were counterstained with hematoxylin (blue).
Scale bars: 100 mm. Quantiﬁcation of caspase-3e
positive area in the tumor sections. For each section,
three independent areas were scanned and quantiﬁed
using Image-Pro Plus software version 6.3.0. Error
bars indicate means  SD. **P < 0.01.
DMP1-Cyclin D1 in Breast CancerDiscussion
It has been shown that Dmp1 is a physiological activator of
the Arf promoter.13,31 The Arf promoter is transactivated by
a variety of oncogenic signaling to prevent incipient cells
from undergoing full transformation to cancers. It has been
reported that Ets transcription factors play essential roles in
activating the p16INK4a promoter through an Ets consensus
in response to oncogenic Ras-Raf-MEK kinase signaling.32
Here, we showed that Dmp1 receives signals from cyclin
D1 overexpression and binds to the Dmp1/Ets site on the
Ink4a promoter, which is different from the Ets consensus
characterized in the previous study. Thus the Ink4a gene is
transactivated by different oncogenes through distinct Ets
consensus sequences.
The Dmp1-binding site is within approximately 200 bp
from the transcription initiation site of the murine Ink4a
gene. Although Dmp1 directly binds to both mouse and
human INK4a promoters, the afﬁnity was lower than that in
the Arf promoter. Of note, reduced afﬁnity binding of Dmp1
has been reported on other promoters such as Areg,22
indicating that the extent of Dmp1 involvement in gene
regulation is dependent on the sequences of the promoter,
where CCCG(G/T)ATG(T/C) (Dmp1/Ets core is under-
lined) shows high afﬁnity (eg, the Arf14, CD1318 promoters)The American Journal of Pathology - ajp.amjpathol.organd XXCG(G/T)ATGX (Dmp1/Ets core is underlined; X
could be any nucleotide) has low afﬁnity in Dmp1 binding
(eg, the Ink4a, Areg promoters).
Previous studies from our group showed that Dmp1 regu-
lates the Arf-p53 pathway by activating Arf14 and interacting
with p53 to neutralize its antagonism by Mdm2.33 Although
Dmp1 has been isolated as a cyclin D2ebinding transcription
factor, very little is known about its role in cyclinDemediated
signal transduction and tumorigenesis. Because cyclin D1
does not have aDNA-binding domain, it needs to interact with
transcription factors to regulate gene expression. Dmp1 is the
critical binding partner of Ink4a/Arf transcription. Both Arf
and Ink4a promoters were transactivated by cyclin D1, which
was conﬁrmed by mRNA analyses of pre-malignant mam-
mary glands from cyclin D1 and D1T286A transgenic mice.
In the process of increased p19Arf and p16Ink4a expression
and induction of cell-cycle arrest or apoptosis, wild-type
cyclin D1 and its constitutively active mutant D1T286A
had very similar effect, suggesting that high expression of
wild-type cyclin D1 is sufﬁcient to induce Arf and Ink4a
responses in normal cells to quench potentially oncogenic
signals. In the activation of both Ink4a/Arf promoters, cyclin
D1eDmp1 interaction was necessary for this process due
to lack of DNA binding of cyclin D1. Consistently, the
cyclin D1mutant D1D142e253, deﬁcient in interacting with1347
Table 1 Tumor Characterization in Dmp1þ/þ; and Dmp1þ/;
MMTV-D1 and MMTV-TA Mice
Dmp1þ/þ;MMTV-D1 Dmp1þ/;MMTV-D1
Percentage of tumor-
bearing mice
40% (4/10) 57.9% (11/19)
Mean survival time
(months)
21 19
Tumor spectrum
Adenocarcinoma
of breast
3/4 9/11*
Lymphoma 1/4 1/11
Sarcoma 0/4 1/11
Dmp1þ/þ;MMTV-TA Dmp1þ/;MMTV-TA
Percentage of tumor-
bearing mice
58.3% (7/12) 62.6% (10/16)
Mean survival time
(months)
22.71 19.38
Tumor spectrum
Adenocarcinoma
of breast
6/7 7/10y
Sarcoma 1/7 1/10
Lung carcinoma 0/7 2/10
*The tumors metastasized to other organs, including liver, ovary, and
uterus, in four of nine Dmp1þ/;MMTV-cyclin D1 mice.
yThe tumors metastasized to other organs, including liver, ovary, and
uterus, in one of seven Dmp1þ/;MMTV-D1T286A mice with mammary
adenocarcinomas.
MMTV-D1, MMTV-cyclin D1; MMTV-TA, MMTV-D1T286A.
Figure 6 Mammary tumors induced by cyclin D1 andD1T286Ametastasize
in Dmp1þ/ mice. A: Photomicrographs of mammary and metastatic tumors
from one Dmp1þ/;MMTV-cyclin D1 mouse; tumor cells disseminated
throughout the body to other organs, including the uterus and ovaries. Left
panel: primary mammary tumor (arrows). Right panel: metastasis of tumor
cells (arrows) throughout the abdomen. B: Representative images of immu-
nostaining for H&E and cyclin D1 (red) in metastatic tumors in liver and ovary
from Dmp1þ/;MMTV-cyclin D1 mice. High cyclin D1 expression was detected
only in the tumor region but not adjacent normal tissues. Scale bars: 100 mm.
N, normal; T, tumor. C: Real-time PCR analyses of human cyclin D1 transgene
mRNA levels in normal organs of nontransgenic mice and mammary/meta-
static tumors in Dmp1þ/þ;MMTV-cyclin D1 and Dmp1þ/;MMTV-cyclin D1mice.
Data were normalized against that of b-actin. MG, mammary gland; MMT,
mouse mammary tumor; MT, metastatic tumor. D: Representative images of
immunostaining for keratin 8 (red), keratin 14 (red) andDmp1 (red) in primary
mammary tumors and metastatic tumors from liver and ovary, respectively, of
Dmp1þ/;MMTV-cyclin D1 mice. Nuclei were counterstained with hematoxylin
after keratin 8 and keratin 14 staining. Scale bars: 100 mm.
Zhu et alDmp1, did not activate these two promoters, and cyclin D1
did not bind to these promoters in Dmp1-deﬁcient cells.
Thus, we conclude that Dmp1 plays critical roles in Arf and
Ink4a gene activation in response to cyclin D1 over-
expression. The fact that theMMTV-cyclin D1 andD1T286A
mice eventually developed mammary tumors is possibly
due to loss of Dmp1 or overexpression of Ink4a/Arf repres-
sors (such as Bmi1, Tbx2/3, Twist, Pokemon) during tumor
development. Further studies are needed to clarify the
roles of these repressors in cyclin D1edriven mammary
tumorigenesis.
We found that endogenous cyclin D1 bound to endogenous
DMP1 and E2F1 in MCF7 breast cancer cells (DMP1 is
shown in Supplemental Figure S6; E2F1 data not shown).
C/EBPb is known to bind to cyclin D1,4 and our data showed
that cyclin D1 did not activate the Arf promoter with deleted
C/EBP-consensus sequence (data not shown). Thus, we
cannot exclude the possibility that other transcriptional
factors are also involved in cyclin D1emediated activation of
the Arf promoter. Recent studies indicated that cyclin D1
interacts with transcription factors including NF-Y, STAT,
CREB2, ELK1, ZNF423, and CUX1,11 andwe also identiﬁed
their consensus sequences in the Arf/Ink4a promoters (data
not shown). Because our data showed the Dmp1-dependent
Arf/Ink4a activation, future studies will be needed to deter-
mine whether Dmp1 collaborates with C/EBPs or other
transcription factors in regulating Arf/Ink4a expression.1348Our results showed the levels of p21Cip1 induction did not
change signiﬁcantly betweenDmp1þ/þ andDmp1/MEFs,
consistent with a previous study that Arf-induced cell-cycle
arrest independent of p21Cip1.34 ARF directly binds to DP1ajp.amjpathol.org - The American Journal of Pathology
DMP1-Cyclin D1 in Breast Cancerand inhibits DP1-E2F1 interaction.35 The activity of E2F1
can also be inhibited by INK4a.14 Therefore, it would be
needed to study the roles of E2F1 and its target genes in
cyclin D1 overexpression-induced cell-cycle arrest.
We showed that both cyclin D1e and D1T286A-driven
mammary carcinogenesis was accelerated in Dmp1þ/ mice.
Importantly, mammary tumors fromDmp1þ/mice exhibited
signiﬁcantly increased Ki-67 in comparison to those from
Dmp1þ/þ mice because Ki-67 is one of the target genes for
E2Fs,36 suggesting that the activity of E2Fs stimulated by
cyclin D1 is suppressed by Dmp1. Our study showed that the
Dmp1 locus was deleted in 4 of 19 (21%) mammary tumors
from MMTV-cyclin D1 andMMTV-D1T286A mice, in which
neither Ink4a/Arf nor p53 deletion was observed. Frequent
deletion of one Dmp1 allele was also observed inMMTV-neu
tumors,17 suggesting the critical role of Dmp1-loss in cyclin
D1e and neu-induced mammary tumorigenesis. The current
study showed that the p16Ink4a was only signiﬁcantly down-
regulated in Dmp1/ mammary glands, but not in Dmp1þ/
tissues, in comparison to Dmp1þ/þ samples, whereas p19Arf
was signiﬁcantly down-regulated in both Dmp1þ/ and
Dmp1/mammary glands. Similar ﬁndings were observed in
mammary tumors from MMTV-neu mice as well as in the
lungs from three different Dmp1 backgrounds.16,17 The differ-
ence of p16Ink4a expression in Dmp1þ/ background from that
in Dmp1/ background may explain more accelerated tumor
development in Dmp1/ mice than that in Dmp1þ/ mice
although the difference was not statistically signiﬁcant.13,16
Given the link between Ras signaling and Dmp1, it is
noteworthy that neither overexpression of cyclin D1 nor
hemizygous loss of Ink4a and Arf accelerated tumorigenesis
in MMTV-ErbB2 mice.37 The above study is consistent
with a previous report that HER2/neu-driven mammary
carcinogenesis was not observed in cyclin D1enull mice,38
suggesting that cyclin D1 is a critical target of HER2/neu/
ErbB2 in promoting mammary tumorigenesis. Our pub-
lished study showed that both Ink4a and Arf inductions in
response to HER2/neu overexpression were markedly atten-
uated (>80%) inmammary tissue fromDmp1/mice.17 Our
current study also showed the reduced p16Ink4a/p19Arf mRNA
levels in pre-malignant mammary tissues fromMMTV-cyclin
D1 and D1T286A mice in both Dmp1þ/ and Dmp1/
backgrounds compared to that in Dmp1 wild-type mice
(Figure 4, C and D). The above data explain the difference
between no acceleration of cyclin D1einduced mammary
tumor developed in Ink4a/Arfþ/mice37 and the signiﬁcantly
accelerated carcinogenesis in Dmp1þ/ mice (Figure 5A).
Meanwhile, the data also suggest that other targets of
Dmp1 may be involved in cyclin D1einduced mammary
carcinogenesis.
Our study also showed the signiﬁcantly increased metas-
tasis of keratin-positive cyclin D1einduced mammary
tumors in Dmp1þ/ mice in comparison to Dmp1þ/þ mice.
Most cyclin D1 tumors were adenosquamous ductal carci-
nomas that metastasized to liver, ovary, uterus, and intestines,
although we did not see any brain/bone metastasis that isThe American Journal of Pathology - ajp.amjpathol.orgcommonly found in human breast cancer patients. Never-
theless, our results imply an important role of Dmp1 in pre-
venting the mammary tumor metastasis induced by cyclin
D1 and provide a potential mechanism of breast cancer
metastasis. Currently, the frequency of human breast cancer
with high cyclin D1 overexpression with or without hDMP1
deletion, their prognostic values, and correlation with clinical
stages of patients are unknown. Thus, it will be necessary to
analyze human breast cancer samples for the correlation
between cyclin D1/Dmp1 alterations and patient survival data
to determine the clinical values of our discovery.Acknowledgments
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